Original articleAlimentary tractFactors Associated With Short- and Long-Term Outcomes of Therapy for Crohn’s Disease
Keywords
Abbreviations used in this paper
Cited by (0)
Conflicts of interest These authors disclose the following: Walter Reinisch has served as a speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Centocor (now Janssen Biotech, Inc.), Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult, as a consultant for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Bioclinica, Biogen IDEC, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Janssen Biotech, Inc., Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Robarts Clinical Trial, Schering-Plough, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Vifor, Zyngenia, and 4SC, as an advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Janssen Biotech, Inc., Celltrion, Danone Austria, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Schering-Plough, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zyngenia, and 4SC, and has received research funding from Abbott Laboratories, Abbvie, Aesca, Janssen Biotech, Inc., Falk Pharma GmbH, MSD; Jean-Frederic Colombel has served as consultant or advisory board member for Abbvie, ABScience, Amgen, Bristol Meyers Squibb, Celltrion, Danone, Ferring, Genentech, Giuliani SPA, Given Imaging, Janssen, Immune Pharmaceuticals, Medimmune, Merck & Co., Millenium Pharmaceuticals Inc., Neovacs, Nutrition Science Partners Ltd., Pfizer Inc. Prometheus Laboratories, Protagonist, Receptos, Sanofi, Schering Plough Corporation, Second Genome, Shire, Takeda, Teva Pharmaceuticals, Tigenix, UCB Pharma, Vertex, Dr. August Wolff GmbH & Co, as speaker for Abbvie, Ferring, Janssen, Merck & Co., Nutrition Science Partners Ltd., Takeda; William Sandborn has received consulting fees from Abbott, ActoGeniX NV, AGI Therapeutics, Inc, Alba Therapeutics Corp, Albireo, Alfa Wasserman, Amgen, AM-Pharma BV, Anaphore, Astellas, Athersys, Inc, Atlantic Healthcare Ltd, Aptalis, BioBalance Corp, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Celek Pharmaceuticals, Cellerix SL, Cerimon Pharmaceuticals, ChemoCentryx, CoMentis, Cosmo Technologies, Coronado Biosciences, Cytokine Pharmasciences, Eagle Pharmaceuticals, EnGene, Inc, Eli Lilly, Enteromedics, Exagen Diagnostics, Inc, Ferring Pharmaceuticals, Flexio Therapeutics, Inc, Funxional Therapeutics Ltd, Genzyme Corp, Gilead Sciences, Given Imaging, GlaxoSmithKline, Human Genome Sciences, Ironwood Pharmaceuticals, Janssen Biotech, Inc., KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Lycera Corp, Meda Pharmaceuticals, Merck Research Laboratories, Merck Serono, Millenium Pharmaceuticals, Nisshin Kyorin Pharmaceuticals, Novo Nordisk, NPS Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, Inc, PDL Biopharma, Pfizer, Procter and Gamble, Prometheus Laboratories, ProtAb Ltd, Purgenesis Technologies, Inc, Relypsa, Inc, Roche, Salient Pharmaceuticals, Salix Pharmaceuticals, Santarus, Schering Plough, Shire Pharmaceuticals, Sigmoid Pharma Ltd, Sirtris Pharmaceuticals, SLA Pharma UK Ltd, Targacept, Teva Pharmaceuticals, Therakos, Tilliotts Pharma AG, TxCell SA, UCB Pharma, Viamet Pharmaceuticals, Vascular Biogenics Ltd, Warner Chilcott UK Ltd, and Wyeth, has received research grants from Abbott, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen Biotech, Inc., Millenium Pharmaceuticals, Novartis, Pfizer, Procter and Gamble, Shire Pharmaceuticals, and UCB Pharma; payments for lectures from and served on the speakers bureau for Abbott, Bristol-Myers Squibb, and Janssen Biotech, Inc., and holds stock/stock options in Enteromedics; Gerassimos Mantzaris has served as a consultant for Merck Sharpe and Dohme, Danon, and OMEGA Pharma; as advisory board member for AbbVie, Abbott laboratories, Merck Sharp and Dohme, UCB, Pharmacosmos, and Takeda; as speaker for AbbVie, Merck Sharpe and Dohme, Ferring International, Falk Pharma, Angelini, and OMEGA Pharma. he has and has received research support from AstraZeneca, AbbVie, Merck Sharpe and Dohme, Menarini, and Genesis; Asher Kornbluth has served as a consultant and advisory board member for Abbvie, Janssen Biotech, Inc., Millenium/Takeda, Pfizer, and Prometheus, he has received Speaker's Bureau fees from Abbvie, Janssen Biotech, Inc., Millenium/Takeda, Santarus, Prometheus, and Salix Pharmaceuticals, and research support from Abbvie, Janssen Biotech, Inc., Pfizer, and Bristol Myers Squibb; Omoniyi Adedokun and Kezhen Tang are employees of Janssen Pharmaceutical Research & Development, LLC; Michael Miller is a former employee of Janssen Pharmaceutical Research & Development, LLC; Freddy Cornillie is an employee of Janssen Biologics BV; and Paul Rutgeerts has served as a lecturer and consultant for Abbott Laboratories, Janssen Biotech, Inc., Merck Research Laboratories, UCB Pharma, Millenium/Takeda, Genentech, Bristol Myers Squibb, Robarts, Tillotts, Pfizer, and Falk Pharma, and has received research funding, from Abbott Laboratories, Janssen Biotech, Inc., Merck Research Laboratories, UCB Pharma.
Funding Supported by Janssen Biotech, Inc (Horsham, PA).
Author names in bold designate shared co-first authorship.